Charles River Laboratories Forecasts Strong 2026 Profits Amid Rising Biotech Demand
Charles River expects 2026 profits to beat estimates as biotech demand stabilizes. The firm named a new CFO and CLO ahead of a planned CEO transition in May.
Insights:
Charles River Laboratories International, Inc. announced on Feb. 18, 2026, that it expects adjusted 2026 earnings to fall between $10.70 and $11.20 per share. This forecast is above the average estimate from analysts at the midpoint, signaling a positive shift in the company's near-term financial outlook. The company, which operates primarily in the US 
US, attributed the optimistic guidance to improved demand and stabilizing bookings for its drug discovery and development services.
US, attributed the optimistic guidance to improved demand and stabilizing bookings for its drug discovery and development services.The updated guidance comes alongside fourth-quarter results that exceeded analysts' revenue estimates. Charles River Laboratories reported a decrease in client cancellations, which has contributed to the stabilization of biopharmaceutical demand. According to data from LSEG, the midpoint of the new earnings range surpasses the previous consensus among Wall Street analysts.
